20/20 Biolabs, Inc.

AIDX · NASDAQ

20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.

Follow Add to Watchlist Ask Question

NASDAQ AIDX Coverage Bootstrap Diagnostics Multi-Cancer Detection Laboratory Developed Tests

Latest ReportMay 15, 2026AIDX: OneTest has revenue growth, but the new Nasdaq float is dilution mathView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.